Ozanimod CAS NO.1306760-87-1

Anhui Haikang Pharmaceutical Co.,
Ltd. is a collection of scientific
research,production and sales
High-Tech Enterprise,which
established in 2009,and covers an
area of 28,000 ㎡.Company locates
in Anqing city,on the bond of
Yangtze River, invested 80 million
RMB to set up synthesis workshops
and clean workshops.All the
productions strictly conform to GMP
standard and equipped with
high-class R&D center.The first
branch was founded in 2010,called
Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.
Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.
To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Ozamold is a potential phosphoeosamine 1 receptor agonist for multiple sclerosis (MS) and ulcerative colitis, inducing Chemicalbook isolation of peripheral blood lymphocytes and reducing the number of activated lymphocytes circulating to the gastrointestinal tract. From the detailed results of the consolidation period of the TOUCHSTONE clinical trial, clinical remission criteria or consolidation rates were significantly higher in the Ozamod treatment group in week 32 than in the placebo group.

Development prospects The industry is also very optimistic about the business prospects of Ozamod. Dr. Stephen Hanauer, medical director of the Northwestern Medical Digestive Health Center, said: "The data of the consolidation period of the trial and the previously reported induction period data indicate that the oral drug Ozamod is expected To help patients with moderate to severe ulcerative Chemicalbook ulcerative colitis. Ozamod is mainly used for the treatment of multiple sclerosis, ulcerative colitis and Crohn’s disease. Among them, multiple sclerosis and ulcerative colitis are not only long-term , The morbidity rate is high, and long-term medication is needed. It can be seen that Ozamod has a huge market capacity and promising prospects.